CY1108748T1 - Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων - Google Patents

Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων

Info

Publication number
CY1108748T1
CY1108748T1 CY20091100132T CY091100132T CY1108748T1 CY 1108748 T1 CY1108748 T1 CY 1108748T1 CY 20091100132 T CY20091100132 T CY 20091100132T CY 091100132 T CY091100132 T CY 091100132T CY 1108748 T1 CY1108748 T1 CY 1108748T1
Authority
CY
Cyprus
Prior art keywords
prevention
treatment
inhibitors
vascular diseases
regular
Prior art date
Application number
CY20091100132T
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of CY1108748T1 publication Critical patent/CY1108748T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση σχετίζεται με τη χρήση αναστολέα της IL-18 στην παρασκευή φαρμάκου για την αντιμετώπιση και/ή πρόληψη περιφερικών αγγειακών παθήσεων. Η εφεύρεση περαιτέρω σχετίζεται με τη χρήση αναστολέα της IL-18 για την αποτροπή ακρωτηριασμού μέλους.
CY20091100132T 2002-03-22 2009-02-05 Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων CY1108748T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100290 2002-03-22
EP03714958A EP1487541B1 (en) 2002-03-22 2003-03-13 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

Publications (1)

Publication Number Publication Date
CY1108748T1 true CY1108748T1 (el) 2014-04-09

Family

ID=28051827

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100132T CY1108748T1 (el) 2002-03-22 2009-02-05 Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων

Country Status (28)

Country Link
US (2) US9592267B2 (el)
EP (1) EP1487541B1 (el)
JP (1) JP4885424B2 (el)
KR (1) KR20050004809A (el)
CN (1) CN100540058C (el)
AR (1) AR039103A1 (el)
AT (1) ATE414556T1 (el)
AU (1) AU2003219162B2 (el)
BR (1) BRPI0308663B8 (el)
CA (1) CA2478855C (el)
CY (1) CY1108748T1 (el)
DE (1) DE60324777D1 (el)
DK (1) DK1487541T3 (el)
EA (1) EA008495B1 (el)
ES (1) ES2314191T3 (el)
HK (1) HK1075422A1 (el)
HR (1) HRP20040758B1 (el)
IL (2) IL164211A0 (el)
ME (1) ME00548B (el)
MX (1) MXPA04009135A (el)
NO (1) NO336226B1 (el)
PL (1) PL207303B1 (el)
PT (1) PT1487541E (el)
RS (1) RS51755B (el)
SI (1) SI1487541T1 (el)
UA (1) UA80275C2 (el)
WO (1) WO2003080104A2 (el)
ZA (1) ZA200407022B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
KR20050004809A (ko) 2002-03-22 2005-01-12 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 말초 맥관 질환 치료 및/또는 예방에 사용되는 ｉｌ-18저해제
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
JP2007532697A (ja) 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
MX337166B (es) 2009-06-24 2016-02-15 Composicion topica que contiene ibuoprofeno.
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
AU2010292486B2 (en) 2009-08-27 2014-08-07 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
JP2013506687A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
ES2553262T3 (es) 2010-08-25 2015-12-07 F. Hoffmann-La Roche Ag Anticuerpos contra la IL-18R1 y usos de los mismos
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
CN103429247A (zh) 2010-12-29 2013-12-04 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) * 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
WO2016139297A1 (en) * 2015-03-05 2016-09-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
BR9816013A (pt) * 1998-09-01 2003-01-21 Hayashibara Biochem Lab Proteìna de ligação de interleucina-18
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
EA005410B1 (ru) 2000-05-05 2005-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
KR20050004809A (ko) 2002-03-22 2005-01-12 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 말초 맥관 질환 치료 및/또는 예방에 사용되는 ｉｌ-18저해제

Also Published As

Publication number Publication date
IL164211A0 (en) 2005-12-18
JP4885424B2 (ja) 2012-02-29
NO336226B1 (no) 2015-06-22
PL372398A1 (en) 2005-07-25
HK1075422A1 (en) 2005-12-16
UA80275C2 (en) 2007-09-10
AR039103A1 (es) 2005-02-09
CA2478855C (en) 2013-12-17
JP2005520852A (ja) 2005-07-14
BRPI0308663B8 (pt) 2021-05-25
EP1487541B1 (en) 2008-11-19
CN1655845A (zh) 2005-08-17
DK1487541T3 (da) 2009-01-19
ES2314191T3 (es) 2009-03-16
HRP20040758A2 (en) 2005-02-28
AU2003219162A1 (en) 2003-10-08
DE60324777D1 (de) 2009-01-02
BRPI0308663B1 (pt) 2019-07-16
PT1487541E (pt) 2008-12-10
WO2003080104A3 (en) 2004-03-04
ZA200407022B (en) 2006-06-28
BR0308663A (pt) 2005-01-25
MXPA04009135A (es) 2004-12-07
PL207303B1 (pl) 2010-11-30
WO2003080104A2 (en) 2003-10-02
KR20050004809A (ko) 2005-01-12
NO20044459L (no) 2004-10-20
US9592267B2 (en) 2017-03-14
US20060233799A1 (en) 2006-10-19
SI1487541T1 (sl) 2009-02-28
CA2478855A1 (en) 2003-10-02
CN100540058C (zh) 2009-09-16
US9566313B2 (en) 2017-02-14
EA008495B1 (ru) 2007-06-29
US20100291028A1 (en) 2010-11-18
RS51755B (en) 2011-12-31
EP1487541A2 (en) 2004-12-22
ME00548B (me) 2011-10-10
IL164211A (en) 2011-07-31
RS81504A (en) 2006-12-15
EA200401240A1 (ru) 2005-02-24
AU2003219162B2 (en) 2008-01-03
ATE414556T1 (de) 2008-12-15
HRP20040758B1 (hr) 2012-10-31

Similar Documents

Publication Publication Date Title
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
CY1107203T1 (el) Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1113160T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
CY1110133T1 (el) Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ
CY1116233T1 (el) Δισφωσφονικα οξεα για τη θεραπευτικη αγωγη και προληψη της οστεοπορωσης
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
GT200300023A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
CY1113342T1 (el) Μεθοδος θεραπειας αθηροσκληρωσης δυσλιπιδαιμιων και σχετικων παθησεων
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
CY1113894T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ροφλουμιλαστη και λεβοκετιριζινη
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
CY1111902T1 (el) Χρηση ακυλοφωσφοχολινων σε συνδυασμο με αντινεοπλασματικα φαρμακα
CY1119125T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια προκαλουμενων απο mcp-1 φλεγμονωδων νοσων
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
BRPI0416680A (pt) inibidores da forma mutante de kit
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
CY1108191T1 (el) Χρηση λεβοκετιρισινης για την θεραπεια επιμονης αλλεργικης ρινιτιδας